Experts at the 2026 Crohn’s & Colitis Congress argued that so-called “treatment-refractory” IBD is often not true drug failure, but rather the result of factors such as bowel fibrosis, structural damage, immunogenicity, poor drug delivery, delayed therapy changes, or psychosocial barriers. They emphasized that persistent…

    DDW 2026

    Headlines in GI

    Subscribe to Newsletter

    * indicates required

    Thought Leadership

    ARTIFICIAL INTELLIGENCE (AI)

    Tech & Innovation